Calculate your SIP ReturnsExplore

Sun Pharma’s GL0034 (Utreglutide) Shows Obesity Treatment Efficacy

25 June 20243 mins read by Angel One
Sun Pharma reports Phase 1 findings on GL0034 (Utreglutide) at ADA's 84th Scientific Sessions, showcasing promise for treating obesity and related conditions.
Sun Pharma’s GL0034 (Utreglutide) Shows Obesity Treatment Efficacy
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

Sun Pharmaceutical Industries Limited announced in a stock exchange filing the outcomes of a Phase 1 study assessing GL0034 (Utreglutide) in obese adults. Presented at the 84th Scientific Sessions of the American Diabetes Association (ADA) on June 21, 2024, in Orlando, FL, the study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics.

The company stated that obesity represents a rapidly escalating global health issue, implicated in various metabolic disorders such as type 2 diabetes mellitus (T2DM), cardiovascular diseases, and metabolic dysfunction-associated steatohepatitis (MASH). Effective treatments are essential in managing obesity and its related health conditions, with GLP-1 (glucagon-like peptide-1) receptor agonists emerging as a promising therapeutic approach for addressing obesity.

GL0034 (Utreglutide) is a novel differentiated incretin analogue with potent, long-acting agonist activity at the GLP-1 receptor. This innovative compound is under evaluation for its potential to offer significant clinical benefits beyond weight loss and gluco-metabolic benefits in individuals with obesity.

Commenting on this development, the MD, Medical Director, AdventHealth Diabetes Institute and Senior Investigator, Diabetes Program Lead, Translational Research Institute, Richard E. Pratley, said, “The recent GL0034 study has shown encouraging results with significant weight loss and notable improvements in lipid profiles among obese participants. This investigational therapy stands out as a potentially differentiated asset in the weight management field. The positive outcomes emphasise the potential of this treatment and set the stage for further research and development.”

The Managing Director of Sun Pharma, Dilip Shanghvi, said, “The promising data from our GL0034 study highlights our commitment to addressing the growing global health challenge of obesity. These findings not only demonstrate the activity of GL0034 in promoting weight loss but also underscore its potential in improving crucial cardiometabolic parameters and risk factors. We are dedicated to advancing this innovative therapy to bring meaningful benefits to patients worldwide.”

About Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries is a prominent global company specialising in speciality generics. It has a presence in Innovative products, Generics, and Consumer Healthcare sectors. The company’s vertically integrated operations ensure the delivery of high-quality medicines trusted by physicians and consumers across more than 100 countries.

On June 24, 2024, the share price of Sun Pharmaceutical Industries Ltd opened at ₹1,475.05, touching the day’s high at ₹1,497.95, as of 10:08 AM on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.

Open Free Demat Account!

Enjoy Zero Brokerage on Equity Delivery

Join our 2 Cr+ happy customers

Enjoy Zero Brokerage on Equity Delivery
Enjoy Zero Brokerage on Equity Delivery

Get the link to download the App

Send App Link
Open Free Demat Account!
Enjoy Zero Brokerage on Stock Investments.